Identification of a Therapeutic Interfering Particle — a single-administration SARS-CoV-2 antiviral intervention with a high barrier to resistanceA defective viral particle derived from SARS-CoV-2 competes with the full virus for resources to replicate, showing therapeutic potential by inhibiting viral proliferation in culture, and reducing viral load and pathology in animal models for infection.A defective viral particle derived from SARS-CoV-2 competes with the full virus for resources to replicate, showing therapeutic potential by inhibiting viral proliferation in culture, and reducing viral load and pathology in animal models for infection.Sonali Chaturvedi, Gustavo Vasen, Michael Pablo, Xinyue Chen, Nathan Beutler, Arjun Kumar, Elizabeth Tanner, Sylvia Illouz, Donna Rahgoshay, John Burnett, Leo Holguin, Pei-Yi Chen, Blaise Ndjamen, Melanie Ott, Robert Rodick, Thomas Rogers, David M. Smith, Leor Weinbergerhttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2821%2901319-2%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignNovember 10, 2021

Powered by WPeMatico